Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: Results of a phase II study

Antonio Rozzi, Daniele Santini, Margherita Salerno, Francesca Bordin, Andrea Mancuso, Giuseppe Minniti, Chiara Nardoni, Michela Corona, Pina Tiziana Falbo, Federica Recine, Gaetano Lanzetta

Research output: Contribution to journalArticlepeer-review

Abstract

Until the recent approval of vinflunine, no standard second-line chemotherapy existed for advanced transitional cell carcinoma (TCC). Few data exist about third-line chemotherapy for metastatic disease. Although administered in up-front regimens, anthracyclines were never evaluated beyond second-line treatment. This study assessed the activity of pegylated liposomal doxorubicin (PLD) in patients with advanced TCC previously treated with two chemotherapy regimens. From May 2005 to June 2009, 23 patients with metastatic TCC were recruited: median age was 62 years (49-76 years) with a median ECOG PS of 1. Patients received PLD 35 mg/m2 every 21 days. All patients were evaluable for efficacy and toxicity. No patient showed complete response. Three patients (13 %) had partial response; seven patients (30 %) showed stable disease for a disease control rate of 43 %. The median time to progression (TTP) was 4.1 months with a median survival time (MST) of 6.3 months. Treatment was well tolerated: no patient developed grade 4 toxicities. This is the first study which evaluated the role of anthracyclines as third-line chemotherapy in metastatic TCC. Despite its manageable profile of toxicity, PLD showed modest activity. Beyond second-line chemotherapy, supportive care still represents the best therapeutic option for patients with metastatic TCC.

Original languageEnglish
Article number407
JournalMedical Oncology
Volume30
Issue number1
DOIs
Publication statusPublished - Mar 2013

Keywords

  • Pegylated liposomal doxorubicin
  • Third-line chemotherapy
  • Transitional cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Fingerprint

Dive into the research topics of 'Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: Results of a phase II study'. Together they form a unique fingerprint.

Cite this